论文部分内容阅读
目的:两种蛋白酶抑制剂治疗基因1型丙型肝炎病毒(HCV)感染患者的Ⅲ期临床试验已经完成,并且在欧美等地区批准上市。欧洲肝脏研究学会(EASL)于2013年对HCV感染管理指南进行了修订更新。本文旨在对2013年版EASL丙型肝炎病毒感染管理临床实践指南进行部分解读。方法:从HCV治疗目标及终点、治疗适应证、不同基因分型HCV患者的治疗策略角度进行解读。结果与结论:聚乙二醇干扰素/利巴韦林(PegIFN/RBV)联合特拉泼维(TVR)或波赛泼维(BOC)是所批准的对基因1型HCV患者的标准治疗,PegIFN/RBV二联疗法仍然是非基因1型HCV患者的标准治疗。
PURPOSE: Phase III clinical trials of two protease inhibitors in the treatment of patients with genotype 1 hepatitis C virus (HCV) infection have been completed and are approved for listing in Europe, the United States and other regions. The European Association for the Study of the Liver (EASL) revised and updated the guidelines for the management of HCV infection in 2013. This article aims to partially interpret the 2013 edition of the EASL Guidelines for Clinical Practice of Hepatitis C Virus Infection Management. Methods: From the treatment of HCV target and end point, indications for treatment, different genotyping HCV patients treatment strategy perspective interpretation. RESULTS AND CONCLUSION: PegIFN / RBV combined with Travolta (TVR) or Boceprevir (BOC) is the approved standard treatment for patients with genotype 1 HCV, PegIFN / RBV dual therapy remains the standard treatment for non-genotype 1 HCV patients.